肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

索拉非尼可改善纤维瘤患者的无进展生存期

2018-04-03 MedSci MedSci原创

索拉非尼纤维瘤无进展生存期
关注

近日，一项随机临床试验显示，与安慰剂组相比，索拉非尼甲苯磺酸盐可显著延长硬纤维瘤或侵袭性纤维瘤（DT/DF）患者的无进展生存期，无进展生存期是患者在疾病恶化之前存活的时间长度。

索拉非尼可改善纤维瘤患者的无进展生存期


近日，一项随机临床试验显示，与安慰剂组相比，索拉非尼甲苯磺酸盐可显著延长硬纤维瘤或侵袭性纤维瘤（DT/DF）患者的无进展生存期，无进展生存期是患者在疾病恶化之前存活的时间长度。


索拉非尼是一种口服给药的靶向治疗药物，能够干扰肿瘤生长需要的新生血管的生长。它被美国食品和药物管理局批准用于治疗晚期肾癌、肝癌和甲状腺癌的患者。之所以选择索拉非尼进行该项临床试验，是因为在之前对索拉非尼治疗的患者进行的回顾性研究中，研究人员发现患者的硬纤维瘤缩小，患者疼痛和其他症状减轻。


纽约纪念斯隆凯特琳癌症中心的肿瘤医学家，首席研究员Mrinal M. Gounder博士说：“这个III期临床试验的良好结果代表了硬纤维瘤患者治疗方法的正式转变，索拉非尼是一种治疗这种罕见癌症的新方式”。在美国，每年约有1000例患者被确诊为DT/DF，其中许多患者相对年轻。纤维瘤通常出现在四肢或腹部，偶尔与家族性腺瘤性息肉病或Gardner综合征相关。DT/DF具有局部侵袭性，可导致疼痛并降低移动性，并可侵入重要组织或器官，导致肠梗阻和其他严重并发症。



原始出处：

https://www.europeanpharmaceuticalreview.com/news/74135/sorafenib-improves-rare-sarcomas/

本文系梅斯医学（MedSci）原创编译整理，转载需授权!


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1378166, encodeId=c62c13e81665f, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Apr 05 12:44:00 CST 2018, time=2018-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387706, encodeId=5276138e706ac, content=<a href='/topic/show?id=f210e72532e' target=_blank style='color:#2F92EE;'>#纤维瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77253, encryptionId=f210e72532e, topicName=纤维瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fc62500009, createdName=12498474m30暂无昵称, createdTime=Thu Apr 05 12:44:00 CST 2018, time=2018-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459669, encodeId=4f33145966919, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59168, encryptionId=565f5916816, topicName=无进展生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c466182591, createdName=zhangfenasdf, createdTime=Thu Apr 05 12:44:00 CST 2018, time=2018-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302588, encodeId=c04b302588c2, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Wed Apr 04 07:15:36 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302552, encodeId=0eb530255202, content=不错耶.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Wed Apr 04 06:20:22 CST 2018, time=2018-04-04, status=1, ipAttribution=)]
    2018-04-05 仁者大医

    #生存期#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1378166, encodeId=c62c13e81665f, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Apr 05 12:44:00 CST 2018, time=2018-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387706, encodeId=5276138e706ac, content=<a href='/topic/show?id=f210e72532e' target=_blank style='color:#2F92EE;'>#纤维瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77253, encryptionId=f210e72532e, topicName=纤维瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fc62500009, createdName=12498474m30暂无昵称, createdTime=Thu Apr 05 12:44:00 CST 2018, time=2018-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459669, encodeId=4f33145966919, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59168, encryptionId=565f5916816, topicName=无进展生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c466182591, createdName=zhangfenasdf, createdTime=Thu Apr 05 12:44:00 CST 2018, time=2018-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302588, encodeId=c04b302588c2, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Wed Apr 04 07:15:36 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302552, encodeId=0eb530255202, content=不错耶.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Wed Apr 04 06:20:22 CST 2018, time=2018-04-04, status=1, ipAttribution=)]
    2018-04-05 12498474m30暂无昵称

    #纤维瘤#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1378166, encodeId=c62c13e81665f, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Apr 05 12:44:00 CST 2018, time=2018-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387706, encodeId=5276138e706ac, content=<a href='/topic/show?id=f210e72532e' target=_blank style='color:#2F92EE;'>#纤维瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77253, encryptionId=f210e72532e, topicName=纤维瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fc62500009, createdName=12498474m30暂无昵称, createdTime=Thu Apr 05 12:44:00 CST 2018, time=2018-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459669, encodeId=4f33145966919, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59168, encryptionId=565f5916816, topicName=无进展生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c466182591, createdName=zhangfenasdf, createdTime=Thu Apr 05 12:44:00 CST 2018, time=2018-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302588, encodeId=c04b302588c2, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Wed Apr 04 07:15:36 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302552, encodeId=0eb530255202, content=不错耶.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Wed Apr 04 06:20:22 CST 2018, time=2018-04-04, status=1, ipAttribution=)]
    2018-04-05 zhangfenasdf

    #无进展生存期#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1378166, encodeId=c62c13e81665f, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Apr 05 12:44:00 CST 2018, time=2018-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387706, encodeId=5276138e706ac, content=<a href='/topic/show?id=f210e72532e' target=_blank style='color:#2F92EE;'>#纤维瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77253, encryptionId=f210e72532e, topicName=纤维瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fc62500009, createdName=12498474m30暂无昵称, createdTime=Thu Apr 05 12:44:00 CST 2018, time=2018-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459669, encodeId=4f33145966919, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59168, encryptionId=565f5916816, topicName=无进展生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c466182591, createdName=zhangfenasdf, createdTime=Thu Apr 05 12:44:00 CST 2018, time=2018-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302588, encodeId=c04b302588c2, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Wed Apr 04 07:15:36 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302552, encodeId=0eb530255202, content=不错耶.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Wed Apr 04 06:20:22 CST 2018, time=2018-04-04, status=1, ipAttribution=)]
    2018-04-04 yfjms

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1378166, encodeId=c62c13e81665f, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Apr 05 12:44:00 CST 2018, time=2018-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387706, encodeId=5276138e706ac, content=<a href='/topic/show?id=f210e72532e' target=_blank style='color:#2F92EE;'>#纤维瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77253, encryptionId=f210e72532e, topicName=纤维瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fc62500009, createdName=12498474m30暂无昵称, createdTime=Thu Apr 05 12:44:00 CST 2018, time=2018-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459669, encodeId=4f33145966919, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59168, encryptionId=565f5916816, topicName=无进展生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c466182591, createdName=zhangfenasdf, createdTime=Thu Apr 05 12:44:00 CST 2018, time=2018-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302588, encodeId=c04b302588c2, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Wed Apr 04 07:15:36 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302552, encodeId=0eb530255202, content=不错耶.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Wed Apr 04 06:20:22 CST 2018, time=2018-04-04, status=1, ipAttribution=)]
    2018-04-04 owlhealth

    不错耶.学习了

    0

相关资讯

EUR J Cancer：放疗联合卡培他滨和索拉非尼治疗晚期KRAS突变的直肠癌：I / II期临床试验（SAKK 41/08）

局部晚期直肠癌的（LARCs）中，KRAS突变的发生频率约为40%，多靶点酪氨酸激酶抑制剂索拉非尼具有放射增敏作用并可能改善KRAS突变的LARC患者标准手术前放化疗的效果。 研究人员在一项I / II期临床试验（SAKK 41/08）中招募了包含有T3 / 4和/或N1 / 2M0 KRAS突变的LARC成年患者，在Ⅰ期临床中关于放疗联合卡培他滨和索拉非尼的剂量增加研究被直接用于II期研究

Gastroenterol：一种驱虫药有望高效地治疗肝细胞癌

作为一种与肝病和肝硬化相关联的癌症，肝细胞癌（HCC）经常在晚期时才表现出症状。在全世界，它是癌症死亡的第二大原因，但是迄今为止，它并没有一种有效的疗法。 美国加州大学旧金山分校计算健康科学研究所主任Atul Butte博士说，正如没有治疗方法的其他疾病那样，需要理解和治疗这种癌

Aliment Pharmacol Ther：索拉非尼的毒性可预测肝癌患者生存率改善

2017年4月，发表在《Aliment Pharmacol Ther》的一项多中心、前瞻性研究表明，索拉非尼的毒性能够预测肝细胞癌（HCC）患者生存率的改善。

Eur J Cancer：瑞格菲尼/索拉非尼抑制脑膜瘤细胞的生长与侵袭

对于不可切除和/或侵袭性脑膜瘤的全身化疗结果，目前仍然不令人满意。PDGF受体（PDGFR）介导的有丝分裂信号传导在脑膜瘤中已被证明处于激活状态。因此，研究者们评估了临床上表征良好的受体酪氨酸激酶抑制剂瑞格菲尼/索拉非尼是否具有PDGFR的抑制作用，研究者们使用IOMM-Lee脑膜瘤细胞模型，通过磁共振成像监测，评估了瑞格菲尼/索拉非尼的细胞毒性作用，抑制增殖作用，诱导细胞凋亡以及抑制细胞侵袭的作

Mol Clin Oncol：肝癌TACE术后早期应用索拉非尼可增加局部控制？

近期，来自日本鹿儿岛大学的Tamai T等人开展了一项前瞻性研究，旨在评价索拉非尼对于经肝动脉化疗栓塞（TACE）治疗后的不可切除肝细胞癌（HCC）的疗效，相关研究近日发表在Mol Clin Oncol杂志。

CLIN CANCER RES：乙酰水杨酸联合索拉非尼治疗RAS突变肿瘤

CLIN CANCER RES近期发表了一篇文章，研究索拉非尼联合抗炎性止疼药治疗难治性RAS突变肿瘤的效果。